INMED PHARMACEUTICALS INC. Payments of Stock Issuance Costs
INMED PHARMACEUTICALS INC. (INM) reported Payments of Stock Issuance Costs of $137.18 thousand for the 12-month period ending 2026-06-30, per its S-4/A filed 2026-09-09.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2026-09-09
- INMED PHARMACEUTICALS INC. payments of stock issuance costs for the quarter ending 2026-06-30 was $1.00, a 100.00% decline year-over-year.
- INMED PHARMACEUTICALS INC. payments of stock issuance costs for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- INMED PHARMACEUTICALS INC. payments of stock issuance costs for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- INMED PHARMACEUTICALS INC. payments of stock issuance costs for the quarter ending 2025-09-30 was $137.18K, a 28.49% decline year-over-year.
| Period end | Payments of Stock Issuance Costs | Payments of Stock Issuance Costs 0 month | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1.00 derived: S-4/A 12 month − S-4 9 month · filed 2026-09-09 | $1.00 derived: sum of 2 quarters · filed 2026-09-09 | $1.00 derived: sum of 3 quarters · filed 2026-09-09 | $137.18K S-4/A · filed 2026-09-09 | ||
| 2026-03-31 | $0.00 derived: S-4 9 month − 10-Q 6 month · filed 2026-07-02 | $0.00 derived: sum of 2 quarters · filed 2026-07-02 | $137.18K S-4 · filed 2026-07-02 | $756.60K derived: sum of 4 quarters · filed 2026-09-09 | ||
| 2025-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-11 | $137.18K 10-Q · filed 2026-02-11 | $756.60K derived: sum of 3 quarters · filed 2026-09-09 | $771.70K derived: sum of 4 quarters · filed 2026-09-09 | ||
| 2025-09-30 | $137.18K 10-Q · filed 2025-11-06 | $756.60K derived: sum of 2 quarters · filed 2026-09-09 | $771.70K derived: sum of 3 quarters · filed 2026-09-09 | $829.33K derived: sum of 4 quarters · filed 2026-09-09 | ||
| 2025-06-30 | $619.42K derived: S-4/A 12 month − S-4 9 month · filed 2026-09-09 | $634.52K derived: sum of 2 quarters · filed 2026-09-09 | $692.15K derived: sum of 3 quarters · filed 2026-09-09 | $883.98K S-4/A · filed 2026-09-09 | ||
| 2025-03-31 | $15.10K derived: S-4 9 month − 10-Q 6 month · filed 2026-07-02 | $72.73K derived: sum of 2 quarters · filed 2026-07-02 | $264.56K S-4 · filed 2026-07-02 | |||
| 2024-12-31 | $57.63K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-11 | $249.46K 10-Q · filed 2026-02-11 | ||||
| 2024-09-30 | $191.82K 10-Q · filed 2025-11-06 | |||||
| 2024-06-30 | $562.15K S-4 · filed 2026-07-02 | |||||
| 2022-06-06 | $127.88K 10-K · filed 2022-09-23 | |||||
| 2021-09-13 | $77.24K 10-Q · filed 2022-11-14 | |||||
| 2021-07-02 | $247.34K 10-K · filed 2022-09-23 | $247.34K 10-Q · filed 2022-05-13 | ||||
| 2021-02-12 | $337.85K 10-K · filed 2021-09-24 | |||||
| 2020-11-16 | $1.11M 10-K · filed 2021-09-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |